Verus Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
Other funds holding ABBV
VCM
VPM
Verus Capital Partners's ABBV Position: Q1 2026 in Review
Verus Capital Partners reduced its AbbVie (ABBV) stake by 4.4% in Q1 2026, selling an estimated $546K and leaving 53,144 shares worth $11.6M. The position accounts for 0.79% of the portfolio, ranked #29.
Verus Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 19 quarters since. The position peaked at $15M in Q1 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Verus Capital Partners held 53,144 shares of AbbVie worth $11.6M as of Q1 2026.
- Verus Capital Partners sold 2,462 AbbVie shares in Q1 2026, an estimated $546K.
- AbbVie made up 0.79% of Verus Capital Partners's portfolio in Q1 2026, its #29 holding.
- Verus Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 19 quarters since.
- Verus Capital Partners's AbbVie position peaked at $15M in Q1 2022.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.